PMID- 35415922
OWN - NLM
STAT- MEDLINE
DCOM- 20220627
LR  - 20230324
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 198
IP  - 1
DP  - 2022 Jul
TI  - International guidelines regarding the role of IVIG in the management of Rh- and 
      ABO-mediated haemolytic disease of the newborn.
PG  - 183-195
LID - 10.1111/bjh.18170 [doi]
AB  - Haemolytic disease of the newborn (HDN) can be associated with significant 
      morbidity. Prompt treatment with intensive phototherapy (PT) and exchange 
      transfusions (ETs) can dramatically improve outcomes. ET is invasive and 
      associated with risks. Intravenous immunoglobulin (IVIG) may be an alternative 
      therapy to prevent use of ET. An international panel of experts was convened to 
      develop evidence-based recommendations regarding the effectiveness and safety of 
      IVIG to reduce the need for ETs, improve neurocognitive outcomes, reduce 
      bilirubin level, reduce the frequency of red blood cell (RBC) transfusions and 
      severity of anaemia, and/or reduce duration of hospitalization for neonates with 
      Rh or ABO-mediated HDN. We used a systematic approach to search and review the 
      literature and then develop recommendations from published data. These 
      recommendations conclude that IVIG should not be routinely used to treat Rh or 
      ABO antibody-mediated HDN. In situations where hyperbilirubinaemia is severe (and 
      ET is imminent), or when ET is not readily available, the role of IVIG is 
      unclear. High-quality studies are urgently needed to assess the optimal use of 
      IVIG in patients with HDN.
CI  - (c) 2022 The Authors. British Journal of Haematology published by British Society 
      for Haematology and John Wiley & Sons Ltd.
FAU - Lieberman, Lani
AU  - Lieberman L
AUID- ORCID: 0000-0002-3633-0728
AD  - Department of Clinical Pathology, University Health Network, Toronto, Ontario, 
      Canada.
AD  - Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, 
      Ontario, Canada.
AD  - Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health 
      Sciences Centre, Toronto, Ontario, Canada.
FAU - Lopriore, Enrico
AU  - Lopriore E
AD  - Division of Neonatology, Department of Pediatrics, Leiden University Medical 
      Center, Leiden, The Netherlands.
FAU - Baker, Jillian M
AU  - Baker JM
AD  - Department of Pediatrics, Unity Health Toronto (St. Michael's Hospital), Toronto, 
      Ontario, Canada.
AD  - Division of Haematology-Oncology, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Bercovitz, Rachel S
AU  - Bercovitz RS
AD  - Division of Hematology, Oncology, and Stem Cell Transplant, Department of 
      Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, 
      Illinois, USA.
FAU - Christensen, Robert D
AU  - Christensen RD
AD  - Divisions of Neonatology and Hematology/Oncology, University of Utah Health, Salt 
      Lake City, UT, USA.
AD  - Department of Women and Newborn's Research, Intermountain Healthcare, Salt Lake 
      City, Utah, USA.
FAU - Crighton, Gemma
AU  - Crighton G
AD  - Department of Haematology, Royal Children's Hospital, Melbourne, Australia.
FAU - Delaney, Meghan
AU  - Delaney M
AD  - Division of Pathology & Laboratory Medicine, Children's National Hospital, 
      Washington, District of Columbia, USA.
AD  - Department of Pathology & Pediatrics, The George Washington University Health 
      Sciences, Washington, District of Columbia, USA.
FAU - Goel, Ruchika
AU  - Goel R
AD  - Division of Transfusion Medicine, Department of Pathology, School of Medicine, 
      Johns Hopkins University, Baltimore, Maryland, USA.
AD  - Simmons Cancer Institute at SIU School of Medicine, Springfield, Illinois, USA.
FAU - Hendrickson, Jeanne E
AU  - Hendrickson JE
AUID- ORCID: 0000-0002-7928-3132
AD  - Departments of Laboratory Medicine and Pediatrics, Yale University, New Haven, 
      Connecticut, USA.
FAU - Keir, Amy
AU  - Keir A
AD  - SAHMRI Women and Kids, South Australian Health and Medical Institute, North 
      Adelaide, South Australia, Australia.
AD  - Adelaide Medical School and the Robinson Research Institute, the University of 
      Adelaide, North Adelaide, South Australia, Australia.
FAU - Landry, Denise
AU  - Landry D
AD  - Canadian Blood Services, Ottawa, Ontario, Canada.
FAU - La Rocca, Ursula
AU  - La Rocca U
AD  - Department of Translational and Precision Medicine, Sapienza University, Rome, 
      Italy.
AD  - Italian National Blood Centre, National Institute of Health, Rome, Italy.
FAU - Lemyre, Brigitte
AU  - Lemyre B
AD  - Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Maier, Rolf F
AU  - Maier RF
AD  - Children's Hospital, University Hospital, Philipps University, Marburg, Germany.
FAU - Muniz-Diaz, Eduardo
AU  - Muniz-Diaz E
AD  - Department of Immunohematology, Blood and Tissue Bank of Catalonia, Barcelona, 
      Spain.
FAU - Nahirniak, Susan
AU  - Nahirniak S
AD  - Alberta Precision Laboratories and Department of Laboratory Medicine and 
      Pathology, University of Alberta, Edmonton, Alberta, Canada.
FAU - New, Helen V
AU  - New HV
AUID- ORCID: 0000-0001-6290-8004
AD  - Clinical Directorate, NHS Blood and Transplant, London, UK.
AD  - Centre for Haematology, Imperial College London, London, UK.
FAU - Pavenski, Katerina
AU  - Pavenski K
AD  - Department of Laboratory Medicine and Pathology, Unity Health Toronto (St. 
      Michael's Hospital), Toronto, Ontario, Canada.
FAU - Dos Santos, Maria Cristina Pessoa
AU  - Dos Santos MCP
AD  - IFF/Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
FAU - Ramsey, Glenn
AU  - Ramsey G
AD  - Department of Pathology, Feinberg School of Medicine, Northwestern University, 
      Chicago, Illinois, USA.
FAU - Shehata, Nadine
AU  - Shehata N
AD  - Departments of Medicine, Laboratory Medicine and Pathobiology, Institute of 
      Health, Policy Management and Evaluation, University of Toronto, Mount Sinai 
      Hospital, Toronto, Ontario, Canada.
CN  - International Collaboration for Transfusion Medicine Guidelines (ICTMG)
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220412
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Blood Group Incompatibility
MH  - *Erythroblastosis, Fetal/drug therapy
MH  - Exchange Transfusion, Whole Blood
MH  - Female
MH  - Humans
MH  - *Immunoglobulins, Intravenous/therapeutic use
MH  - Infant, Newborn
MH  - Phototherapy
PMC - PMC9324942
OTO - NOTNLM
OT  - alloimmunization
OT  - evidence-based guidelines
OT  - haemolytic disease of the newborn
OT  - intravenous immunoglobulin
OT  - pregnancy
COIS- The authors have no financial or intellectual conflicts of interest to declare.
EDAT- 2022/04/14 06:00
MHDA- 2022/06/28 06:00
PMCR- 2022/07/26
CRDT- 2022/04/13 05:39
PHST- 2022/02/10 00:00 [received]
PHST- 2022/03/16 00:00 [accepted]
PHST- 2022/04/14 06:00 [pubmed]
PHST- 2022/06/28 06:00 [medline]
PHST- 2022/04/13 05:39 [entrez]
PHST- 2022/07/26 00:00 [pmc-release]
AID - BJH18170 [pii]
AID - 10.1111/bjh.18170 [doi]
PST - ppublish
SO  - Br J Haematol. 2022 Jul;198(1):183-195. doi: 10.1111/bjh.18170. Epub 2022 Apr 12.